Launched in April 2005, Astellas was formed through the historical merger of Japan's
third and fifth largest pharmaceutical companies - Yamanouchi, founded in 1923,
and Fujisawa, founded in 1894.
Both companies possessed similarities where it matters most - philosophy and vision.
But the companies also differed where it matters most - areas of therapeutic concentration
Yamanouchi brought a record of developing blockbuster drugs, a pipeline full of
promising new compounds and a sales and marketing culture of deeply grounded, data-driven
Fujisawa brought dominance in transplantation, a soaring reputation for in-depth
understanding of the disease states and treatments within its market niches, and
a track record for developing high-profile, market - leading products that become
new standards of care.
With an unrelenting commitment to R&D as a value-creating core of its business,
Astellas is consolidated around complementary strengths from Yamanouchi and Fujisawa.
Astellas stands on a much stronger, more advanced business platform than either
of the former companies could have mounted individually.
For more information about the history of Astellas including a historical timeline
of the company’s accomplishments please visit the Astellas Pharma Inc. Web site.